#!/usr/bin/env python3
"""
Research Project: Osimertinib + EGFR ADC Combination Adverse Events

Multi-agent research system using agent mail for communication.
Demonstrates context protection through distributed agent architecture.
"""

import time
from datetime import datetime
from core.agent_mail.mailbox import MailboxFactory
from core.agent_mail.audit_trail import AuditTrail
from core.agent_mail.transport import MessageType, MessagePriority

# Initialize agent mail system
print("="*80)
print("INITIALIZING AGENT MAIL SYSTEM")
print("="*80)

audit_trail = AuditTrail("research_project_audit.db")
factory = MailboxFactory(audit_trail=audit_trail)

# Create mailboxes for all agents
orchestrator = factory.create_mailbox("Orchestrator")
lit_agent = factory.create_mailbox("LiteratureAgent")
safety_agent = factory.create_mailbox("SafetyAnalysisAgent")
pharma_agent = factory.create_mailbox("PharmacologyAgent")
stats_agent = factory.create_mailbox("StatisticsAgent")
clinical_agent = factory.create_mailbox("ClinicalAgent")
auditor1 = factory.create_mailbox("AuditAgent1")
auditor2 = factory.create_mailbox("AuditAgent2")

print(f"\n✓ Created {len(factory.get_all_agents())} agent mailboxes")
print(f"  Agents: {', '.join(factory.get_all_agents())}")

# Subscribe to events for monitoring
events_log = []
def log_event(data):
    events_log.append(data)
    if data.get('message_type') in ['task_assignment', 'task_result', 'audit_result']:
        print(f"  📧 {data.get('from', 'Unknown')} → {data.get('to', 'Unknown')}: {data.get('message_type', 'Unknown')}")

factory.event_bus.subscribe("message.sent", log_event)

print("\n" + "="*80)
print("EXECUTING RESEARCH TASKS")
print("="*80)

# TASK 1: Osimertinib Safety Profile
print("\n[TASK 1] Osimertinib Safety Profile")
task1_thread = "task-001-osimertinib-safety"

orchestrator.send(
    to_agent="LiteratureAgent",
    message_type=MessageType.TASK_ASSIGNMENT,
    subject="Osimertinib Safety Profile Research",
    body="""## Assignment

Conduct comprehensive literature review of osimertinib safety profile.

## Requirements
- FDA-approved adverse events (with frequencies)
- Grade 3+ AE rates from clinical trials
- Mechanism of toxicity
- Time to onset patterns
- All claims must be cited with sources
- Express appropriate uncertainty

## Evidence Required
- Clinical trial data
- FDA labeling information
- Peer-reviewed publications from 2020-2024
""",
    data={
        "task_id": "task-001",
        "task_type": "literature_review",
        "search_terms": ["osimertinib", "adverse events", "safety", "toxicity"],
        "evidence_level": "high",
        "max_results": 50
    },
    thread_id=task1_thread,
    priority=MessagePriority.HIGH,
    requires_ack=True
)

print("  ✓ Task assigned to LiteratureAgent")
print("  ⏳ Simulating agent processing...")
time.sleep(0.1)

# Simulate LiteratureAgent responding with findings
lit_agent.send(
    to_agent="AuditAgent1",
    message_type=MessageType.AUDIT_REQUEST,
    subject="Osimertinib Safety Review - Ready for Audit",
    body="""## Literature Review: Osimertinib Safety Profile

### Common Adverse Events (Any Grade)
Based on FLAURA trial (N=279 osimertinib arm):
- Diarrhea: 58% (FLAURA trial, Soria 2018, NEJM)
- Rash/Dermatitis: 49% (FLAURA trial)
- Dry skin: 23%
- Paronychia: 22%
- Stomatitis: 17%

### Grade ≥3 Adverse Events
- Overall Grade ≥3 AE rate: 23% (FLAURA trial)
- Interstitial lung disease (ILD): 3% all grades, <1% Grade ≥3 (FDA label)
- QTc prolongation: 10% (> 480 msec), 1% Grade ≥3
- Cardiac toxicity: 2% serious cardiac events

### Mechanism of Toxicity
- EGFR inhibition in skin, GI tract (on-target, off-tumor)
- Minimal wild-type EGFR inhibition vs 1st/2nd gen TKIs
- CYP3A metabolism may lead to drug interactions

### Time to Onset
- Skin toxicities: Typically within first 4-8 weeks
- ILD: Median onset ~3 months (FDA data)
- GI toxicity: Usually early (first cycle)

### Limitations
- Uncertainty: Real-world rates may differ from trial population
- Confidence: High for common AEs, moderate for rare AEs
- Long-term toxicity data still emerging

### References
1. Soria JC et al. NEJM 2018;378:113-125 (FLAURA trial)
2. FDA Osimertinib Label, revised 2024
3. Ramalingam SS et al. NEJM 2020;382:41-50 (FLAURA OS)
""",
    data={
        "task_id": "task-001",
        "result": {
            "common_aes": ["diarrhea (58%)", "rash (49%)", "dry skin (23%)"],
            "grade3_rate": 0.23,
            "serious_aes": ["ILD (3%)", "QTc prolongation (10%)"],
            "mechanism": "EGFR inhibition in normal tissues",
            "evidence_quality": "high",
            "confidence": "high for common AEs, moderate for rare"
        }
    },
    thread_id=task1_thread
)

print("  ✓ Literature review completed")

# Audit the results
auditor1.send(
    to_agent="Orchestrator",
    message_type=MessageType.AUDIT_RESULT,
    subject="Task 001 Audit: PASSED",
    body="""## Audit Results

### Status: PASSED

### Strengths
- All percentages cited with trial names
- Appropriate uncertainty expressed
- Limitations section included
- References provided
- Evidence chain complete

### Issues Found
- None (minor: could add more recent 2024 data)

### Recommendation
Accept results. High quality evidence-based review.
""",
    data={
        "task_id": "task-001",
        "status": "passed",
        "quality_score": 0.95,
        "issues": []
    },
    thread_id=task1_thread
)

print("  ✓ Audit completed: PASSED")

# TASK 2: EGFR ADC Safety Profile
print("\n[TASK 2] EGFR ADC Safety Profile")
task2_thread = "task-002-adc-safety"

orchestrator.send(
    to_agent="SafetyAnalysisAgent",
    message_type=MessageType.TASK_ASSIGNMENT,
    subject="EGFR ADC Toxicity Analysis",
    body="""## Assignment

Analyze safety profile of EGFR-targeting antibody-drug conjugates.

## Focus Areas
- ADC-specific toxicities (payload, linker, target-related)
- Clinical trial safety data
- Comparison across different EGFR ADCs
- On-target, off-tumor effects

## Evidence Requirements
- Clinical trial publications
- Regulatory filings
- Mechanistic studies
""",
    data={
        "task_id": "task-002",
        "adc_targets": ["EGFR", "wild-type", "mutant"],
        "payloads": ["MMAE", "MMAF", "DXd", "topoisomerase-I"]
    },
    thread_id=task2_thread,
    priority=MessagePriority.HIGH
)

print("  ✓ Task assigned to SafetyAnalysisAgent")
time.sleep(0.1)

safety_agent.send(
    to_agent="AuditAgent2",
    message_type=MessageType.AUDIT_REQUEST,
    subject="EGFR ADC Safety Analysis - Ready for Audit",
    body="""## EGFR ADC Safety Profile

### Key ADCs in Development
1. **MRG003** (Phase I/II): EGFR antibody + MMAE payload
2. **Depatuxizumab Mafodotin (ABT-414)**: EGFR + MMAF (discontinued Phase III)
3. **AZD9592**: Bispecific EGFR/c-MET + TopI payload (Phase I ongoing)

### Major Toxicities

**Interstitial Lung Disease (ILD)**
- Incidence: ~20% reported in EGFR ADC trials
- Mechanism: On-target lung toxicity + payload effects + bystander killing
- Grade ≥3: Variable, 2-5% in published reports
- CRITICAL: ILD is dose-limiting toxicity for several EGFR ADCs

**Ocular Toxicity**
- Incidence: ~20% in TROPION-Lung02 (though different ADC)
- Mechanism: EGFR expression in corneal epithelium
- Usually Grade 1-2, manageable

**Dermatologic Toxicity**
- Higher than antibody alone due to ADC amplification
- Includes severe rash, skin necrosis in some cases
- Frequency: 30-50% any grade (estimated from preclinical/early clinical)

**Hematologic Toxicity**
- Payload-dependent (e.g., MMAE causes neutropenia)
- Grade 3/4 neutropenia: 10-20% with microtubule inhibitor payloads

### Bystander Effects
- Payload release from dying cells affects neighboring cells
- Can increase toxicity to normal tissue
- Particularly concerning in lung, skin, GI tract

### Mitigation Strategies Being Explored
- Protease-activated pro-ADCs (remain inert until tumor protease cleaves)
- Bispecific ADCs to reduce EGFR-related toxicity (e.g., AZD9592)
- Novel linkers with better tumor selectivity

### Evidence Quality
- **High confidence**: ILD is major toxicity (~20% incidence)
- **Moderate confidence**: Other toxicities (limited clinical data, multiple ADCs)
- **LOW confidence**: Exact rates for specific EGFR mutant-targeted ADCs (sparse data)

### Limitations
- Most EGFR ADCs still in early trials
- Limited head-to-head comparison data
- Payload-specific effects vary widely
- Combination toxicity with TKIs largely unknown

### References
1. Fronti Oncol 2023 review (EGFR ADCs in NSCLC)
2. JAMA Oncol 2022 (MRG003 Phase I trial)
3. Various preclinical studies
""",
    data={
        "task_id": "task-002",
        "result": {
            "ild_incidence": 0.20,
            "ocular_toxicity": 0.20,
            "skin_toxicity": "30-50%",
            "grade3_overall": "variable, 20-35%",
            "evidence_quality": "moderate (early trial data)",
            "confidence": "high for ILD, moderate for others"
        }
    },
    thread_id=task2_thread
)

print("  ✓ ADC safety analysis completed")

auditor2.send(
    to_agent="Orchestrator",
    message_type=MessageType.AUDIT_RESULT,
    subject="Task 002 Audit: PASSED WITH RECOMMENDATIONS",
    body="""## Audit Results

### Status: PASSED (with minor recommendations)

### Strengths
- Appropriate uncertainty expressions (HIGH/MODERATE/LOW)
- Multiple ADC types considered
- Limitations clearly stated
- Evidence quality explicitly rated
- Bystander effects discussed (advanced concept)

### Minor Issues
- Some percentages given as ranges (appropriate given data quality)
- Could cite more specific trial identifiers

### Recommendations
- Accept results
- Flag that combination toxicity data is speculative
- Note for synthesis: ILD risk overlap with osimertinib

### Quality Score
0.88 (Good, appropriate for emerging field)
""",
    data={
        "task_id": "task-002",
        "status": "passed",
        "quality_score": 0.88,
        "issues": ["ranges used where exact data unavailable (appropriate)"],
        "recommendations": ["flag ILD overlap", "note data limitations"]
    },
    thread_id=task2_thread
)

print("  ✓ Audit completed: PASSED")

# TASK 3: Pharmacological Interaction Analysis
print("\n[TASK 3] Pharmacological Interaction Analysis")
task3_thread = "task-003-interactions"

orchestrator.send(
    to_agent="PharmacologyAgent",
    message_type=MessageType.TASK_ASSIGNMENT,
    subject="Drug Interaction Analysis: Osimertinib + EGFR ADC",
    body="""## Assignment

Analyze potential pharmacological interactions between osimertinib and EGFR ADCs.

## Focus Areas
- PK/PD interactions
- Overlapping toxicity mechanisms
- Target pathway effects
- Drug metabolism considerations

## Critical: Be Speculative But Transparent
- Clearly label predictions vs established facts
- Use mechanistic reasoning where clinical data absent
""",
    data={
        "task_id": "task-003",
        "drug1": "osimertinib",
        "drug2": "EGFR-targeting ADC"
    },
    thread_id=task3_thread,
    priority=MessagePriority.HIGH
)

print("  ✓ Task assigned to PharmacologyAgent")
time.sleep(0.1)

pharma_agent.send(
    to_agent="AuditAgent1",
    message_type=MessageType.AUDIT_REQUEST,
    subject="Interaction Analysis - Ready for Audit",
    body="""## Pharmacological Interaction Analysis

### CRITICAL CAVEAT
**No published clinical data exists for osimertinib + EGFR ADC combination.**
Analysis below is mechanistic prediction based on known properties of each agent.

### Overlapping Toxicity Mechanisms

**1. EGFR Pathway Inhibition (ADDITIVE)**
- Osimertinib: Mutant EGFR inhibition, minimal WT EGFR effect
- ADC: WT + mutant EGFR binding (antibody component)
- **Prediction**: Additive EGFR-mediated toxicity (skin, GI, possibly ↑ severity)

**2. Interstitial Lung Disease (ILD) - MAJOR CONCERN**
- Osimertinib: ~3% ILD risk (FDA label)
- EGFR ADC: ~20% ILD risk (clinical trial data)
- **Prediction**: HIGH risk of increased ILD incidence/severity
- **Mechanism**: Overlapping lung toxicity from both agents
- **UNCERTAIN**: Additive vs synergistic (no data)

**3. Skin Toxicity (LIKELY ADDITIVE)**
- Both cause EGFR-mediated skin effects
- **Prediction**: 60-80% combined rash/dermatitis (vs ~50% either alone)

### PK/PD Considerations

**Osimertinib Metabolism**
- CYP3A substrate
- Weak CYP3A inducer
- BCRP inhibitor
- **Impact on ADC**: Minimal (ADCs not CYP-metabolized, catabolism via lysosomal degradation)

**ADC Pharmacokinetics**
- Payload clearance may be affected if osimertinib modulates transporters
- **Uncertainty**: No published data on this interaction

**Target Saturation**
- Osimertinib blocks mutant EGFR kinase activity
- ADC requires EGFR binding for internalization
- **Prediction**: ADC can still bind EGFR even if kinase inhibited (different sites)
- **Uncertainty**: Conformational changes from TKI binding could affect ADC uptake

### Potential Synergistic Effects

**Theoretical Benefit**
- Osimertinib-resistant cells may still express EGFR (target for ADC)
- Could provide non-overlapping mechanisms of action

**Theoretical Risk**
- Combined toxicity may be greater than additive
- Immune modulation from both agents (uncertain interaction)

### Evidence Quality: LOW
- **No clinical data** for this specific combination
- Analysis based on mechanistic extrapolation
- High uncertainty in all predictions

### Recommendations for Clinical Use
1. **Start with dose reduction** (if combining)
2. **Intensive pulmonary monitoring** (ILD risk)
3. **Dermatology support** anticipated
4. **Consider sequential vs concurrent** therapy

### Confidence Levels
- Mechanism description: HIGH confidence
- Toxicity predictions: MODERATE to LOW confidence
- Quantitative estimates: LOW confidence (speculative)

### References
1. Osimertinib PK/PD: PMC6302998 (DDI review)
2. ADC pharmacology: General ADC literature
3. **NOTE**: No specific osimertinib + EGFR ADC combination data published
""",
    data={
        "task_id": "task-003",
        "result": {
            "ild_risk": "HIGH (major concern, both agents cause ILD)",
            "skin_toxicity": "likely additive",
            "pk_interaction": "minimal expected",
            "evidence_quality": "LOW (no clinical data, mechanistic only)",
            "confidence": "LOW (speculative)",
            "major_concerns": ["ILD risk", "skin toxicity", "no clinical data"]
        }
    },
    thread_id=task3_thread
)

print("  ✓ Interaction analysis completed")

auditor1.send(
    to_agent="Orchestrator",
    message_type=MessageType.AUDIT_RESULT,
    subject="Task 003 Audit: PASSED - Excellent Transparency",
    body="""## Audit Results

### Status: PASSED

### Exemplary Qualities
- **Outstanding transparency**: Clearly labeled speculation vs fact
- **Appropriate caveats**: "No published clinical data" stated upfront
- **Uncertainty quantification**: LOW confidence explicitly stated
- **Mechanistic rigor**: Sound reasoning from known properties
- **Anti-fabrication compliance**: No made-up percentages, no fake studies

### Strengths
- Distinguished between mechanism (HIGH confidence) and predictions (LOW confidence)
- Flagged ILD as major concern (critical clinical insight)
- Recommended dose reduction and monitoring (actionable)

### No Issues Found

### Quality Score
0.98 (Excellent - model for speculative but transparent analysis)

### Recommendation
Accept. This demonstrates how to handle areas with no direct evidence.
""",
    data={
        "task_id": "task-003",
        "status": "passed",
        "quality_score": 0.98,
        "issues": [],
        "exemplary": True
    },
    thread_id=task3_thread
)

print("  ✓ Audit completed: PASSED (Exemplary)")

# Continue in next part...
print("\n" + "="*80)
print("TASKS 1-3 COMPLETE - Continuing...")
print("="*80)
